13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839948
Total reported value
$4.2B
$4.2B
32 檔
9.9%
As reported in its official Q2 2024 Form 13F filing, TCG Crossover Management, LLC's tracked investment portfolio stood at $4.2B with 32 total positions.
During Q2 2024, TCG Crossover Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including CGON, DYN, ABVX) accounted for 9.9% of total reported equity market value during Q2 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | Stock-Other | 12.08% | -0.84% | +2.80% | |
| 2 | DYN | Dyne Therapeutics Inc | Stock-Other | 9.75% | +0.07% | — | |
| 3 | ABVX | Abivax Sa-adr | Stock-Other | 8.34% | -1.41% | +450.60% | |
| 4 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 6.53% | +0.34% | — | |
| 5 | COGT | Cogent Biosciences Inc | Stock-Other | 6.12% | -0.93% | +12.07% | |
| 6 | SVRA | Savara Inc | Stock-Other | 5.19% | -0.10% | +23.62% | |
| 7 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 4.36% | — | — | |
| 8 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 4.27% | — | — | |
| 9 | KROS | Keros Therapeutics Inc | Stock-Other | 4.19% | — | — | |
| 10 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 3.88% | — | — | |
| 11 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.79% | -0.01% | — | |
| 12 | TYRA | Tyra Biosciences Inc | Stock-Other | 3.31% | -1.07% | — | |
| 13 | KURA | Kura Oncology Inc | Stock-Other | 3.06% | — | — | |
| 14 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.84% | -0.19% | EXIT | |
| 15 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.72% | -4.87% | EXIT | |
| 16 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 2.62% | — | -47.68% | |
| 17 | CMPS | Compass Pathways PLC | Stock-Other | 2.43% | — | — | |
| 18 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.34% | — | — | |
| 19 | IRON | Disc Medicine Inc | Stock-Other | 2.29% | -0.09% | — | |
| 20 | TRML | Tourmaline Bio Inc | Stock-Other | 1.98% | — | — | |
| 21 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 1.58% | — | -29.92% | |
| 22 | ADVMCHF | Adverum Biotechnologies Inc | Stock-Other | 1.44% | — | — | |
| 23 | VTGNUSD | Vistagen Therapeutics Inc | Stock-Other | 0.97% | — | — | |
| 24 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.87% | -0.64% | — | |
| 25 | EYPT | Eyepoint Inc | Stock-Other | 0.84% | — | — | |
| 26 | CCCC | C4 Therapeutics Inc | Stock-Other | 0.61% | — | — | |
| 27 | NKTREUR | Nektar Therapeutics | Stock-Other | 0.52% | — | — | |
| 28 | ✓ | Stock-Other | 0.39% | — | +1.80% | ||
| 29 | ANTX | An2 Therapeutics Inc | Stock-Other | 0.35% | — | — | |
| 30 | KOD | Kodiak Sciences Inc | Stock-Other | 0.22% | -0.23% | — | |
| 31 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.08% | — | -61.24% | |
| 32 | CABA | Cabaletta Bio Inc | Stock-Other | 0.07% | — | — |
According to official SEC Form 13F filings, TCG Crossover Management, LLC reported a total U.S. public equity portfolio value of $4.2B across 32 disclosed positions in Q2 2024.
During Q2 2024, TCG Crossover Management, LLC's top holdings by market value included CGON (12.1%)、DYN (9.8%)、ABVX (8.3%). The largest single position, CGON, represented 12.1% of total portfolio value.
In Q2 2024, TCG Crossover Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.